Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.

Markus Lutz1, Matthias Schwab, Ernst-Ulrich Griese

  • 1Division of Clinical Pharmacology, University Hospital Tübingen, Germany.

Pharmacogenetics
|January 5, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same author

Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Reduced Trust in Bodily Sensations Predicts Suicidal Ideation in Hospitalized Patients With Major Depression: An Observational Study.

Suicide & life-threatening behavior·2025
Same author

Effect of osteopathic manipulative treatment on comorbid depressive symptoms in patients with chronic low back pain: study protocol for a randomised controlled trial.

BMJ open·2025
Same author

Touch medicine: bridging the gap between recent insights from touch research and clinical medicine and its special significance for the treatment of affective disorders.

Frontiers in psychiatry·2024
Same author

Correction: A systematic review of the etiopathogenesis of Kienböck's disease and a critical appraisal of its recognition as an occupational disease related to hand-arm vibration.

BMC musculoskeletal disorders·2024

The risk factors for visual disturbances linked to proton pump inhibitors like omeprazole remain unclear. Genetic analysis of patients experiencing these adverse effects suggests that being a poor metabolizer of CYP2C19 is not a significant risk factor.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Ophthalmology

Background:

  • Visual disturbances are a potential adverse effect of proton pump inhibitors (PPIs).
  • The specific risk factors for developing these visual disturbances remain largely unknown.
  • Omeprazole, a common PPI, is extensively metabolized by the polymorphic enzyme CYP2C19.

Purpose of the Study:

  • To investigate the role of CYP2C19 genetic polymorphism in patients experiencing visual disturbances associated with omeprazole.
  • To identify potential risk factors for omeprazole-induced visual side effects.

Main Methods:

  • Retrospective identification of patients who reported visual disturbances while taking omeprazole.
  • Genotyping of these patients to determine their CYP2C19 metabolic status.

Related Experiment Videos

  • Analysis of the prevalence of CYP2C19 poor metabolizer (PM) genotype among affected patients.

    • Main Results:

    • Twenty-nine patients experiencing omeprazole-associated visual disturbances were identified and genotyped.
    • Two of the 29 patients were found to be poor metabolizers (PMs) of CYP2C19.
    • The prevalence of the PM genotype in this cohort did not suggest it as a primary risk factor.

    Conclusions:

    • The CYP2C19 poor metabolizer genotype does not appear to be a significant risk factor for developing visual disturbances in patients taking omeprazole.
    • Further research is needed to elucidate the underlying mechanisms and identify other potential risk factors for these adverse visual events.